Review: once daily LMWH is as effective as twice daily LMWH for initial treatment of venous thromboembolism
Q Is once daily low molecular weight heparin (LMWH) as effective (for reducing recurrent venous thromboembolism [VTE]) and as safe (with respect to major haemorrhagic events) as twice daily LMWH in the initial treatment of VTE?
Cochrane Peripheral Vascular Diseases Specialized Trials Register (up to April 2005), Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library, Issue 1, 2005), Medline (up to April 2005), EMBASE/Excerpta Medica (up to April 2005), and bibliographies of relevant articles.
Study selection and assessment:
randomised controlled trials (RCTs) in any language that compared (in an intention to treat analysis) once daily with twice daily use of a fixed dose of subcutaneous LMWH as initial treatment in patients with objectively documented VTE (deep venous thromboembolism [DVT] or pulmonary embolism [PE]). Study quality was assessed using the Jadad scale. Trials without adequate …